Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-Kinetic Agents), By Region, And Segment Forecasts, 2025-2034
Global Gastroesophageal Reflux Disease Therapeutics Market Size is valued at USD 4.9 Bn in 2021 and is predicted to reach USD 5.9 Bn by the year 2034 at a 1.9% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- The demand for gastroesophageal reflux disease therapeutics is expected to rise due to the increasing number of initiatives by the government and non-governmental organizations to combat malnutrition.
- Investing in creating new raw materials and producing finished food items are considered driving forces in the market's growth.
- North America dominated the market and accounted for a revenue share of global revenue in 2024.
- The government's rising preference for local components is expected to slow the expansion of the GERD industry.
Due to factors such as the low success rates associated with GERD management devices, an increase in the frequency of GERD and other gastrointestinal problems, and a rising tendency of self-medication supported by a robust product pipeline, the market for GERD treatments is expanding. Lockdowns have brought about significant lifestyle changes. The COVID-19 lockdown, remote work, sedentary lives, boredom, and anxiety directly impact people's eating patterns. There was a significant (P 0.001) rise in the number of meals, snacks, binges, and unhealthy food intake throughout the COVID-19-induced home confinement period.
Determining which people have GERD is one of the most challenging parts of calculating the condition's prevalence. Many patients with GERD-related symptoms do not seek treatment from a primary care physician (PCP). Those who do often send patients to a gastroenterologist only when symptoms stop responding to treatment after seeking PCP therapy (refractory). GERD also has a significant economic impact since the expense of long-term disease management is high because it is a chronic rather than an acute illness.
Recent Developments:
- In Nov 2023, Phathom Pharmaceuticals' Voquezna (vonoprazan) tablets have been authorized by the FDA for the treatment of erosive esophagitis, sometimes referred to as erosive GERD (gastroesophageal reflux disease), in adults. It is also prescribed as a maintenance therapy for erosive gastroesophageal reflux disease (GERD) and for the alleviation of heartburn linked to erosive GERD.
- In Oct 2022, EndoStim has been granted the FDA's Breakthrough Device designation for its EndoStim System, which is used to treat patients suffering from gastroesophageal reflux disease (GERD) who do not experience relief from medication therapy.Competitive Landscape:
Some of the Gastroesophageal Reflux Disease Therapeutics market players are:
- AstraZeneca;
- Aurobindo Pharma Limited
- Cadila Pharmaceuticals Limited
- Camber Pharmaceuticals Inc.
- CHEPLAPHARM Arzneimittel GmbH
- Daewoong Pharmaceutical Co., Ltd
- Eisai Co. Ltd.
- EndoStim, Inc.
- GlaxoSmithKline PLC
- Ironwood Pharmaceuticals, Inc.;
- Jeil Pharmaceutical Co., Ltd.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Phathom Pharmaceuticals Inc.
- Reckitt Benckiser Group PLC
- Sebela Pharmaceuticals
- SFJ Pharmaceuticals Group
- SRS Life Sciences Pte. Ltd.
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceuticals Industries Limited
Market Segmentation:
The Gastroesophageal Reflux Disease Therapeutics market is segmented on the basis of drug type. Based on drug type, the market is categorized as Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-kinetic agents.
Based On Drug Type, The Antacids Segment Is Accounted As A Significant Contributor In The Gastroesophageal Reflux Disease Therapeutics Market
The bioalcohols category is expected to hold a major share in the global Gastroesophageal Reflux Disease Therapeutics market in 2021. The success and speedy relief that antacids offer are credited with the segment's dominance. Customers seeking treatment from acid reflux and heartburn spend billions of dollars on antacids, one of the most popular classes of over-the-counter pharmaceuticals available worldwide. They treat GERD, heartburn, acid indigestion, hyperacidity, and upset stomach symptoms brought on by these conditions. The segment's expansion can also be linked to the public's growing understanding of self-medication. Consumers prefer over-the-counter medications to professional medical services. Antacids have also been discovered to be helpful and have no adverse side effects in pregnancy and other diseases, further fueling the segment's rise.
The North America Gastroesophageal Reflux Disease Therapeutics Market Holds A Significant Revenue Share In The Region
Due to the rising prevalence of GERD in the local population, North America dominated the global gastroesophageal reflux disease treatment market in 2023. This trend can be due to the increasing use of GERD therapies. For instance, research that appeared in the journal GUT found that 18–28% of people in North America had GERD. Furthermore, there are more and more campaigns to raise public awareness of the problem, which is driving up demand for GERD treatments. For instance, EndoGastric Solutions, Inc. began a national campaign to support GERD awareness week in November 2022. The campaign's goal was to give GERD sufferers simple-to-follow reflux-friendly recipes.
Gastroesophageal Reflux Disease Therapeutics Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2024 | USD 4.9 Bn |
| Revenue forecast in 2034 | USD 5.9 Bn |
| Growth rate CAGR | CAGR of 1.9% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Million, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Drug Type |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | AstraZeneca; Eisai Co. Ltd.; GSK plc.; Takeda Pharmaceutical Company Limited.; Ironwood Pharmaceuticals, Inc.; Johnson & Johnson Services; Inc.; SFJ Pharmaceuticals; Sebela Pharmaceuticals; Phathom Pharmaceuticals Inc.; Camber Pharmaceuticals Inc. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Gastroesophageal Reflux Disease Therapeutics Market:
Gastroesophageal Reflux Disease Therapeutics Market By Drug Type-
- Antacids
- H2 Receptor Blockers
- Proton Pump Inhibitors (PPIs)
- Pro-kinetic agents
Gastroesophageal Reflux Disease Therapeutics Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Gastroesophageal Reflux Disease Therapeutics Market Size is valued at USD 4.9 Bn in 2024 and is predicted to reach USD 5.9 Bn by the year 2034
Gastroesophageal Reflux Disease Therapeutics Market expected to grow at a 1.9% CAGR during the forecast period for 2025-2034
AstraZeneca; Eisai Co. Ltd.; GSK plc.; Takeda Pharmaceutical Company Limited.; Ironwood Pharmaceuticals, Inc.; Johnson & Johnson Services; Inc.; SFJ P
Drug Type are the key segments of the Gastroesophageal Reflux Disease Therapeutics Market.
North America region is leading the Gastroesophageal Reflux Disease Therapeutics Market.